Average BCVA, CCT and ECD during the follow-up period in the graft viral DNA+ group and the control group
| Last time of follow-up | Average ECD during follow-up period (cells/mm2) | ||||
|---|---|---|---|---|---|
| BCVA | CCT (μm) | 6 months | 12 months | 24 months | |
| Total | |||||
| Graft viral DNA+ (n=25) | 0.71±0.70 | 605±121 | 2290±481 | 2052±491 | 1716±476 |
| Control (n=48) | 0.70±0.62 | 590±79 | 2547±430 | 2363±372 | 2156±369 |
| PK | |||||
| Graft viral DNA+ (n=9) | 1.01±0.83 | 593±97 | 2232±378 | 1942±439 | 1442±291 |
| Control (n=16) | 0.95±0.62 | 587±44 | 2576±296 | 2320±205 | 2038±166 |
| DASEK | |||||
| Graft viral DNA+ (n=9) | 0.54±0.34 | 667±156 | 2336±512 | 2026±458 | 1659±366 |
| Control (n=18) | 0.59±0.50 | 631±99 | 2656±400 | 2471±331 | 2230±385 |
| DALK | |||||
| Graft viral DNA+ (n=7) | 0.54±0.81 | 541±81 | 2305±545 | 2230±543 | 2140±497 |
| Control (n=14) | 0.55±0.72 | 541±51 | 2375±530 | 2274±511 | 2198±469 |
| HSV-1 | |||||
| Graft viral DNA+ (n=4) | 0.88±1.04 | 607±64 | 2374±409 | 2059±399 | 1588±211 |
| Control (n=7) | 0.77±0.78 | 598±54 | 2571±391 | 2320±135 | 2066±115 |
| CMV | |||||
| Graft viral DNA+ (n=7) | 0.96±0.73 | 606±111 | 2113±329 | 1797±267 | 1486±322 |
| Control (n=15) | 0.93±0.66 | 611±86 | 2550±295 | 2343±264 | 2079±282 |
| VZV | |||||
| Graft viral DNA+ (n=5) | 0.50±0.14 | 637±132 | 2266±565 | 1995±593 | 1427±341 |
| Control (n=8) | 0.54±0.16 | 616±110 | 2651±304 | 2468±326 | 2203±362 |
| EBV | |||||
| Graft viral DNA+ (n=2) | 0.65±0.49 | 642±62 | 2750±40 | 2460±139 | 2012±280 |
| Control (n=4) | 0.57±0.33 | 616±33 | 2893±456 | 2616±349 | 2366±434 |
The average ECD of grafts for HSV-1, CMV, VZV and EBV DNA does not include the data of recipients who underwent DALK.
BCVA, best-corrected visual acuity; CCT, central corneal thickness; CMV, cytomegalovirus; DALK, deep lamellar keratoplasty; ECD, endothelial cell density; EBV, Epstein–Barr virus; HSV, herpes simplex virus; PK, penetrating keratoplasty; VZV, varicella-zoster virus